RE:RE:gaps must be filledThe 'problem' is that are too many nervous investors in this stock still. The price will continue to trickle down till the sellers dry up or till management has something exciting to report. I'd expect an update on hemophilia. Thyroid news they are likely going to wait until their conference in April to disseminate. Another trial result of the next patients should also be in the news pipeline. A deal that brings in $ is the one I have personally been waiting for but who knows if the deadbeat management can pull it off or not. Without said deal we should be back in the 2 to 2.50